PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells

Histone deacetylase inhibitors (HDACi) have become a promising new avenue for cancer therapy, and many are currently in Phase I/II clinical trials for various tumor types. In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Rivera-Del Valle, Nilsa, Gao, Shan, Miller, Claudia P., Fulbright, Joy, Gonzales, Carolina, Sirisawad, Mint, Steggerda, Susanne, Wheler, Jennifer, Balasubramanian, Sriram, Chandra, Joya
Формат: Artigo
Язык:Inglês
Опубликовано: Hindawi Publishing Corporation 2010
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2817379/
https://ncbi.nlm.nih.gov/pubmed/20145726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2010/207420
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы